{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-006598","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.160578+00:00","generated_at":"2026-05-22T08:16:14.402314+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MetaVia Phase 2a DA-1241 hits ALT reduction of 22.8 U/L, CAP score down 23 dB/m in MASH patients","bullets":["DA-1241 100 mg lowered ALT by 22.8 U/L (p<0.05 vs placebo) after 16 weeks in patients with baseline ALT 40-200 U/L.","Liver fat (CAP) reduced 23.0 dB/m with DA-1241 100 mg vs 1.4 dB/m placebo; FAST score dropped from 0.559 to 0.371.","HbA1c decreased 0.54%p at week 16 (baseline 6.99%); in type 2 diabetes subgroup, HbA1c fell 1.08%p.","Inflammation and fibrosis biomarkers (hs-CRP, CCL2, TIMP1) improved significantly (p<0.05 vs placebo).","Well tolerated; no TEAEs leading to discontinuation except one placebo; company plans end-of-Phase 2 FDA meeting H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-006598","json":"https://secwatch.observer/filing/0001558370-25-006598.json","markdown":"https://secwatch.observer/filing/0001558370-25-006598.md","text":"https://secwatch.observer/filing/0001558370-25-006598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025006598/0001558370-25-006598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837025006598/mtva-20250507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:16:14.402314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}